

## PEER-REVIEWED CME SUPPLEMENTS

Eleven years ago, the Senior Editors launched *The Oncologist* to address the needs of community- and hospital-based physicians entrusted with cancer patient care. Today, *The Oncologist* is one of the World's most important physician-reviewed cancer medicine journals. It also is one of the World's most widely read cancer periodicals. In keeping with the multimodality approach of contemporary practice of medical, surgical, and radiation oncology—thereby helping to better prepare physicians and other oncology caregivers in this fast-paced field.

Since its launch, *The Oncologist* has become recognized as a primary source for the busy, practicing oncologist. It was awarded admittance to *Index Medicus/Medline* from its inaugural issue. In the United States, all medical and radiation oncologists and fellows-in-training receive the Journal. The Journal's Editorial Board of world-class thought leaders is reflected in its global readership in 63 countries.

*The Oncologist* is a preferred platform for peer-reviewed CME supplements because of its:

### ***Focus on the Practitioner's Needs***

Structured on a single topic or theme, the Journal's articles are internationally respected, highly regarded by key opinion leaders, and widely used by healthcare professionals.

### ***Scientific Integrity***

All papers are peer-reviewed by the Senior Editors and Editorial Board members who represent the World's thought leaders in medical, surgical, and radiation oncology.

### ***Visibility***

*The Oncologist* is indexed by all major databases including the premier: *Index Medicus/Medline*.

### ***Speed of Production***

*The Oncologist's* speed is unparalleled: 90 days from peer acceptance of final manuscript, Supplements are released.

### ***Global Readership***

*The Oncologist* is a high-impact journal whose Impact Factor places it in the top 10% of cancer medicine journals. All supplements are sent to the Journal's international subscriber base as well as to targeted audiences. Additional copies may be accommodated in the Supplement agreement.

### ***Availability Online***

Supplements are published and freely available in full-text online at [www.TheOncologist.com](http://www.TheOncologist.com).

### ***CME Accreditation***

The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. All activities have been planned and implemented in accordance with the Essential Areas and policies of the ACCME through the joint sponsorship of The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) and *The Oncologist*. Each educational activity designated for a maximum of 1 *AMA PRA Category 1 Credit*<sup>™</sup>. It is the physician's responsibility to only claim credit commensurate with the extent of their participation in the activity.

The AMA has determined that physicians not licensed in the United States who participate in a Continuing Medical Education program are eligible for *AMA PRA Category 1 Credit*<sup>™</sup>.

## **Recent Supplements to *The Oncologist*:**

**Treatment Advances in Solid Tumors During the Past Decade: Benchmark Studies Impacting Survival and Quality of Life**

[The Oncologist 10 \(Suppl 3\)](#) : 1S-58S.

**Reaching for a Cure: New Horizons for Early Stage Neoplastic Disease**

[The Oncologist 10 \(Suppl 2\)](#) : 1S-34S.

**Bisphosphonates in Metastatic Bone Disease: Renal Safety Matters**

[The Oncologist 10 \(Suppl 1\)](#): 1S-24S.

**New Horizons for Topotecan: Important Advances in the Treatment of Lung Cancer**

[The Oncologist 9 \(Suppl 6\)](#) : 1S-52S.

**Beyond Hemoglobin and Quality of Life: Exploring the Spectrum of Clinical Benefits with rHuEpo**

[The Oncologist 9 \(Suppl 5\)](#) : 1S-73S.

**Optimizing Bisphosphonate Therapy in Oncology**

[The Oncologist 9 \(Suppl 4\)](#) : 1S-47S.

**The Future of ErbB-1 and ErbB-2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors**

[The Oncologist 9 \(Suppl 3\)](#) : 1S-26S.

**Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes**

[The Oncologist 9 \(Suppl 2\)](#) : 1S-32S.

**Targeting VEGF in Cancer Treatment**

[The Oncologist 9 \(Suppl 1\)](#) : 1S-49S.

**Penetrating Insights: Crossing the Cancer Cell Membrane to Improve Clinical Outcomes**

[The Oncologist 8 \(Suppl 3\)](#) : 1S-45S.

**Liposomal Anthracyclines for Breast Cancer: Clinical Efficacy and Safety Update**

[The Oncologist 8 \(Suppl 2\)](#) : 1S-30S.

**Cancer Fatigue: The Way Forward**

[The Oncologist 8 \(Suppl 1\)](#) : 1S-33S.